ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Conventional CHOP regimen

Its studies are mostly in Lymphoma, T-Cell, led by Dizal Pharmaceuticals.

Furthest: phase 2, since Mar 16, 20261 company-led study, 1 open or runningNext primary completion: Sep 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Dizal Pharmaceuticals11 open or runningphase 2since Mar 16, 2026Mar 16, 2026Sep 2029phase 2 · NCT07496229

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 16, 2026First study: phase 2 study in Lymphoma, T-CellFirst studyNCT07496229 · 220 planned · China

Ahead

  1. Sep 2029Primary completion: phase 2 study in Lymphoma, T-CellNCT07496229

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07496229Lymphoma, T-Cell · China2RecruitingSep 2029220

How it is read

Names in the registry

  • “Conventional CHOP regimen”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.